Medicilon(SH:688202) Zhong Guo Jing Ji Wang·2025-10-20 07:35Core Points - Meidi Xi (688202.SH) reported a revenue of 540.4 million yuan for the first half of 2025, representing a year-on-year growth of 3.64% [1][3] - The net profit attributable to shareholders was -12.9 million yuan, and the net profit after deducting non-recurring gains and losses was -26.7 million yuan [1][3] - The net cash flow from operating activities was 74.67 million yuan [1][3] Financial Data Summary - Revenue for the first half of 2025: 540.4 million yuan, compared to 521.4 million yuan in the same period last year, an increase of 3.64% [3] - Total profit for the period was -20.55 million yuan, an improvement from -90.03 million yuan year-on-year [3] - The net profit attributable to shareholders was -12.9 million yuan, compared to -70.23 million yuan in the previous year [3] - The net profit after deducting non-recurring gains and losses was -26.73 million yuan, compared to -79.60 million yuan last year [3] - The net cash flow from operating activities improved to 74.67 million yuan from -47.52 million yuan in the same period last year [3] Historical Financial Performance - In 2023 and 2024, the net profit attributable to shareholders is projected to be -33.21 million yuan and -331 million yuan, respectively [3] - Revenue for 2024 is expected to be 1.04 billion yuan, down 24.01% from 1.37 billion yuan in 2023 [5] - The net profit attributable to shareholders for 2024 is projected at -330.85 million yuan, compared to -33.21 million yuan in 2023 [5] Fundraising and IPO Information - Meidi Xi raised a total of 643.25 million yuan through its IPO, with a net amount of 578.75 million yuan after expenses [6] - The company initially planned to raise 346.91 million yuan for various projects, including drug research and working capital [6] - The total fundraising from two rounds of financing amounts to 1.643 billion yuan [9]